NP Medical News about Arthritis, Rheumatoid Certolizumab Pegol

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Use of Antiemetic Agents in Acute Gastroenteritis

3. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

4. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease

5. Rapid correction of low vitamin D status in nursing home residents

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Certolizumab Pegol: In Rheumatoid Arthritis
BioDrugs, 11/10/09

Duggan ST et al. – Certolizumab pegol is a PEGylated humanized Fab? monoclonal antibody that targets and neutralizes both membrane–bound and soluble tumor necrosis factor (TNF)–alpha, preventing inflammation and consequently the destruction of cartilage and bone. Certolizumab pegol has a relatively long elimination half–life of ?2 weeks, allowing subcutaneous administration once every 2 or 4 weeks...In patients with active rheumatoid arthritis who had previously failed to respond to treatment with >=1 disease–modifying anti–rheumatic drug, certolizumab pegol 400 mg every 4 weeks as monotherapy effectively improved ACR responses at all measured timepoints up to 24 weeks, according to data from the randomized, phase III FAST4WARD trial. Certolizumab pegol was generally well tolerated in combination with methotrexate or as monotherapy in phase III trials in patients with rheumatoid arthritis, with most adverse events being of mild to moderate intensity. Infections were the most frequently reported adverse events.

<< Previous
Oral Cancer Prevention Advances with a Translational Trial of...

Next >>
Management of H1N1 influenza virus respiratory syndrome